|
gptkbp:instanceOf
|
gptkb:peptide
gptkb:drug
|
|
gptkbp:administeredBy
|
subcutaneous injection
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:United_States
gptkb:FDA
2022
|
|
gptkbp:ATCCode
|
A10BK07
|
|
gptkbp:brand
|
gptkb:Mounjaro
|
|
gptkbp:CASNumber
|
2023788-19-2
|
|
gptkbp:chemicalClass
|
peptide mimetic
|
|
gptkbp:clinicalTrialPhase
|
gptkb:SURMOUNT-1
gptkb:SURMOUNT-2
gptkb:SURPASS-1
gptkb:SURPASS-2
gptkb:SURPASS-3
gptkb:SURPASS-4
gptkb:SURPASS-5
|
|
gptkbp:contraindication
|
gptkb:medullary_thyroid_carcinoma
gptkb:multiple_endocrine_neoplasia_syndrome_type_2
|
|
gptkbp:developer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:eliminatedIn
|
renal excretion
proteolytic cleavage
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:frequency
|
once weekly
|
|
gptkbp:halfLife
|
about 5 days
|
|
gptkbp:hasMolecularFormula
|
C225H348N48O68
|
|
gptkbp:indication
|
weight loss
glycemic control
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:GLP-1_receptor_agonist
GIP receptor agonist
|
|
gptkbp:patent
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:pregnancyCategory
|
N
not recommended
|
|
gptkbp:proteinBinding
|
low
|
|
gptkbp:riskFactor
|
pancreatitis
gastrointestinal adverse effects
hypoglycemia (with insulin or sulfonylureas)
|
|
gptkbp:routeOfAdministration
|
subcutaneous
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
abdominal pain
constipation
dyspepsia
decreased appetite
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:synonym
|
gptkb:LY3298176
|
|
gptkbp:UNII
|
2Z07MY7019
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes
weight management
|
|
gptkbp:bfsParent
|
gptkb:Mounjaro
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
tirzepatide
|